LEUKEMIAS

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.

The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.

The FDA granted fast track status to HC-7366 for relapsed/refractory AML treatment.

While there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid leukemia.

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs among these patients.

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute lymphoblastic leukemia treatment.

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Recent advancements have improved the way physicians treat acute lymphoblastic leukemia.

The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic leukemia, has been approved by the FDA.

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

Habte Yimer, MD, discussed the findings from the phase 3 ALPINE trial and explored how these results are shaping clinical decisions in chronic lymphocytic leukemia treatment.

BGB-16673 has been granted FDA fast track designation based on findings from a phase 1/2 study of the oral agent in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Sangeetha Venugopal, MD, MS, discusses what she is most interested about regarding unmet needs in patients with AML.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.

Sangeetha Venugopal, MD, MS, discusses the evolving field of acute myeloid leukemia treatment.

When given in combination, sonrotoclax and zanubrutinib shows promise in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, according to data from the BGB-11417-101 study.

Claire Saxton, MBA, discusses a study on the concept of social toxicity in patients with acute myeloid leukemia.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discussed the real-world effectiveness of brexu-cel for relapsed/refractory B-cell acute lymphocytic leukemia.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.

Findings from the phase 3 E1910 study showed that blinatumomab extended overall survival when added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia.

Following a futility analysis, the phase 2 SELECT-AML-1 trial of tamibarotene combined with venetoclax and azacitidine in newly diagnosed RARA-overexpressed acute myeloid leukemia will discontinue enrollment.

The AUGMENT-101 trial demonstrated that revumenib achieved a 23% complete remission rate in patients with relapsed/refractory KMT2A-rearranged acute leukemia, with a well-tolerated safety profile and durable responses.

The FDA has granted an orphan drug designation to alemtuzumab, a chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA has extended the PDUFA target action date for the new drug application of revumenib for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia to December 26, 2024.